PL1680140T3 - Inhibitory receptora-1 czynnika wzrostu fibroblastów i związane z nim sposoby leczenia - Google Patents

Inhibitory receptora-1 czynnika wzrostu fibroblastów i związane z nim sposoby leczenia

Info

Publication number: PL1680140T3
Authority: PL; Poland
Prior art keywords: fgfr; methods; treatment; growth factor; factor receptor
Prior art date: 2003-10-16

Application number

PL04796034T

Other languages

English (en)

Inventor

Haijun Sun

Juqun Shen

James R Tonra

Original Assignee

Imclone Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-16

Filing date

2004-10-18

Publication date

2011-11-30

2004-10-18 Application filed by Imclone Llc filed Critical Imclone Llc

2011-11-30 Publication of PL1680140T3 publication Critical patent/PL1680140T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Diabetes (AREA)
Hematology (AREA)
Epidemiology (AREA)
Obesity (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Dermatology (AREA)
Biochemistry (AREA)
Physical Education & Sports Medicine (AREA)
Child & Adolescent Psychology (AREA)
Gynecology & Obstetrics (AREA)

PL04796034T 2003-10-16 2004-10-18 Inhibitory receptora-1 czynnika wzrostu fibroblastów i związane z nim sposoby leczenia PL1680140T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US51225503P	2003-10-16	2003-10-16
EP04796034A EP1680140B1 (en)	2003-10-16	2004-10-18	Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof
PCT/US2004/034970 WO2005037235A2 (en)	2003-10-16	2004-10-18	Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof

Publications (1)

Publication Number	Publication Date
PL1680140T3 true PL1680140T3 (pl)	2011-11-30

Family

ID=34465334

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL04796034T PL1680140T3 (pl)	2003-10-16	2004-10-18	Inhibitory receptora-1 czynnika wzrostu fibroblastów i związane z nim sposoby leczenia

Country Status (13)

Country	Link
US (2)	US20070274981A1 (pl)
EP (3)	EP2229955A1 (pl)
JP (1)	JP4686465B2 (pl)
AT (1)	ATE506077T1 (pl)
CA (2)	CA2762955A1 (pl)
CY (1)	CY1111479T1 (pl)
DE (1)	DE602004032370D1 (pl)
DK (1)	DK1680140T3 (pl)
ES (1)	ES2361917T3 (pl)
PL (1)	PL1680140T3 (pl)
PT (1)	PT1680140E (pl)
SI (1)	SI1680140T1 (pl)
WO (1)	WO2005037235A2 (pl)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7658924B2 (en)	2001-10-11	2010-02-09	Amgen Inc.	Angiopoietin-2 specific binding agents
US20050282733A1 (en) *	2002-06-27	2005-12-22	Prins Johannes B	Differentiation modulating agents and uses therefor
CA2762955A1 (en)	2003-10-16	2005-04-28	Imclone Llc	Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof
KR101167573B1 (ko) *	2003-11-07	2012-07-30	노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드	개선된 약학적 성질을 갖는 퀴놀리논 화합물의 약학적으로허용가능한 염
EP1790983A4 (en) *	2004-07-30	2008-05-07	Japan Tobacco Inc	METHOD FOR SCREENING A COMPOUND PREVENTING INFECTION OF CELLS WITH HEPATITIS C VIRUS (HCV)
EP1882475A1 (en) *	2006-07-26	2008-01-30	Novartis AG	Method of treating disorders mediated by the fibroblast growth factor receptor
WO2009046141A2 (en) *	2007-10-01	2009-04-09	Isis Pharmaceuticals, Inc.	Antisense modulation of fibroblast growth factor receptor 4 expression
JO2913B1 (en)	2008-02-20	2015-09-15	امجين إنك,	Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
JOP20190083A1 (ar)	2008-06-04	2017-06-16	Amgen Inc	بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
FR2933702A1 (fr) *	2008-07-08	2010-01-15	Sanofi Aventis	Antagonistes specifiques du recepteur fgf-r4
EP2358749B1 (en)	2008-10-10	2018-07-18	Amgen, Inc	Fgf21 mutants and uses thereof
CA2755133A1 (en)	2009-03-20	2010-09-23	Amgen Inc.	Selective and potent peptide inhibitors of kv1.3
WO2010122090A1 (en)	2009-04-24	2010-10-28	Glaxo Group Limited	Fgfr1c antibody combinations
BRPI1011404B1 (pt)	2009-05-05	2022-05-03	Amgen Inc	Polipeptídeos mutantes fgf21, polipeptídeo de fusão, multímero, composição farmacêutica, ácido nucleico isolado, vetor e célula hospedeira
AU2010246038A1 (en)	2009-05-05	2011-12-01	Amgen Inc.	FGF21 mutants and uses thereof
EP2443145A1 (en)	2009-06-17	2012-04-25	Amgen, Inc	Chimeric fgf19 polypeptides and uses thereof
US20120301463A1 (en)	2009-09-30	2012-11-29	President And Fellows Of Harvard College	Methods for Modulation of Autophagy Through the Modulation of Autophagy-Enhancing Gene Products
JP2013512672A (ja)	2009-12-02	2013-04-18	アムジエン・インコーポレーテツド	ヒトＦＧＦＲ１ｃ、ヒトβ−クロト−、ならびにヒトＦＧＦＲ１ｃおよびヒトβ−クロト−の両方に結合する結合タンパク質
UA109888C2 (uk)	2009-12-07	2015-10-26		ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
AU2014250730B2 (en) *	2009-12-07	2016-10-13	Amgen Inc.	Human antigen binding proteins that bind beta-Klotho, FGF receptors and complexes thereof
JP2013523184A (ja)	2010-04-15	2013-06-17	アムジエン・インコーポレーテツド	ヒトＦＧＦ受容体およびβ−ＫＬＯＴＨＯ結合性タンパク質
WO2012015674A1 (en)	2010-07-26	2012-02-02	Eli Lilly And Company	THERAPEUTIC USES OF AN FGFR1c ANTIBODY
CA2885176C (en)	2010-09-22	2018-10-23	Amgen Inc.	Carrier immunoglobulins and uses thereof
KR102058658B1 (ko)	2010-12-15	2019-12-24	다이가쿠쿄도리요우키칸호우진 죠우호우시스테무 겡큐키코우	단백질의 생산 방법
RU2440142C1 (ru) *	2011-02-07	2012-01-20	Общество С Ограниченной Ответственностью "Онкомакс"	Антитело, останавливающее или замедляющее рост опухоли (варианты), способ подавления роста опухоли, способ диагностики злокачественных образований
SG185832A1 (en) *	2011-05-10	2012-12-28	Agency Science Tech & Res	Fgfr1 antibodies and treatment of cancer
WO2012138975A1 (en) *	2011-04-07	2012-10-11	Genentech, Inc.	Anti-fgfr4 antibodies and methods of use
EP2710042A2 (en)	2011-05-16	2014-03-26	Fabion Pharmaceuticals, Inc.	Multi-specific fab fusion proteins and methods of use
DK2710035T3 (en) *	2011-05-16	2017-06-19	Hoffmann La Roche	FGFR1 agonists and methods of use
CA2839437A1 (en)	2011-06-16	2012-12-20	Isis Pharmaceuticals, Inc.	Antisense modulation of fibroblast growth factor receptor 4 expression
EP2723391B1 (en) *	2011-06-24	2018-06-13	University of Miami	Fibroblast growth factor receptor inhibition for the treatment of disease
WO2013033008A2 (en)	2011-08-26	2013-03-07	Merrimack Pharmaceuticals, Inc.	Tandem fc bispecific antibodies
KR20150123250A (ko)	2013-03-06	2015-11-03	제넨테크, 인크.	암 약물 내성의 치료 및 예방 방법
MX2015011712A (es)	2013-03-06	2016-04-04	Merrimack Pharmaceuticals Inc	Anticerpos biespecificos fc en fila anti-c-met.
PE20160190A1 (es)	2013-08-01	2016-04-28	Five Prime Therapeutics Inc	Anticuerpos anti-fgfr2iiib afucosilados
TWI670283B (zh)	2013-12-23	2019-09-01	美商建南德克公司	抗體及使用方法
WO2015148708A1 (en)	2014-03-25	2015-10-01	Regeneron Pharmaceuticals, Inc.	Fgf21 receptor agonists and uses thereof
JP2017517552A (ja)	2014-06-13	2017-06-29	ジェネンテック，インコーポレイテッド	抗癌剤耐性の治療及び防止方法
NZ733841A (en)	2015-01-16	2024-01-26	Juno Therapeutics Inc	Antibodies and chimeric antigen receptors specific for ror1
RU2017134379A (ru) *	2015-03-25	2019-04-03	Новартис Аг	Формилированные n-гетероциклические производные в качестве ингибиторов fgfr4
WO2017049296A1 (en)	2015-09-20	2017-03-23	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Monoclonal antibodies specific for fibroblast growth factor receptor 4 (fgfr4) and methods of their use
EP3371217B1 (en)	2015-11-08	2025-06-11	F. Hoffmann-La Roche AG	Methods of screening for multispecific antibodies
BR112018010410A8 (pt)	2015-11-23	2019-02-26	Five Prime Therapeutics Inc	método para tratar câncer em um sujeito, composição e métodos de aumento do número de células nk e de aumento do número de uma ou mais células positivas para pd-l1
MA43416A (fr)	2015-12-11	2018-10-17	Regeneron Pharma	Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
CN108699149B (zh)	2016-02-02	2023-01-06	弗雷德哈钦森癌症中心	抗-ror1抗体及其用途
JP7034489B2 (ja)	2016-03-15	2022-03-14	アイタブメッド（エイチケイ）リミテッド	多重特異性Ｆａｂ融合タンパクおよびその使用
WO2018095932A1 (en)	2016-11-22	2018-05-31	Merck Patent Gmbh	Monoclonal antibody directed to fgfr1
TW201833140A (zh)	2017-01-09	2018-09-16	美商莫瑞麥克製藥公司	抗fgfr抗體及使用方法
CN110621336B (zh)	2017-05-16	2024-05-14	戊瑞治疗有限公司	癌症治疗中抗fgfr2抗体与化学治疗剂的组合
EP3444275A1 (en)	2017-08-16	2019-02-20	Exiris S.r.l.	Monoclonal antibody anti-fgfr4
EP3847196A4 (en)	2018-09-07	2023-01-04	ITabMed (HK) Limited	BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
CN114901692A (zh) *	2019-12-24	2022-08-12	迪哲(江苏)医药股份有限公司	新颖抗fgfr2b抗体
WO2021129656A1 (en) *	2019-12-24	2021-07-01	Dizal (Jiangsu) Pharmaceutical Co., Ltd.	Novel anti-fgfr2b antibodies
TW202307007A (zh)	2021-05-04	2023-02-16	美商再生元醫藥公司	多特異性fgf21受體促效劑及其等用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4275149A (en)	1978-11-24	1981-06-23	Syva Company	Macromolecular environment control in specific receptor assays
US4946778A (en) *	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
DE3853515T3 (de)	1987-05-21	2005-08-25	Micromet Ag	Multifunktionelle proteine mit vorbestimmter zielsetzung.
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) *	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
KR100272077B1 (ko)	1990-08-29	2000-11-15	젠팜인터내셔날,인코포레이티드	이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5545806A (en) *	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) *	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
EP0798002B1 (en) *	1991-01-17	2002-04-24	The Board Of Regents Of The University Of Washington	Anti platelet derived growth factor antibodies in the treatment of restenosis
US6077692A (en) *	1995-02-14	2000-06-20	Human Genome Sciences, Inc.	Keratinocyte growth factor-2
SK284073B6 (sk) *	1996-04-12	2004-09-08	Warner-Lambert Company	Polycyklické zlúčeniny, ich použitie a farmaceutické kompozície na ich báze
US6486185B1 (en) *	1997-05-07	2002-11-26	Sugen, Inc.	3-heteroarylidene-2-indolinone protein kinase inhibitors
CA2309792A1 (en) *	1997-11-12	1999-05-20	William C. Shakespeare	Novel signal transduction inhibitors, compositions containing them
US6514981B1 (en) *	1998-04-02	2003-02-04	Sugen, Inc.	Methods of modulating tyrosine protein kinase function with indolinone compounds
US6569868B2 (en) *	1998-04-16	2003-05-27	Sugen, Inc.	2-indolinone derivatives as modulators of protein kinase activity
WO2000027802A1 (en) *	1998-11-12	2000-05-18	Ariad Pharmaceuticals, Inc.	Bicyclic signal transduction inhibitors, compositions containing them & uses thereof
UA71971C2 (en) *	1999-06-04	2005-01-17	Agoron Pharmaceuticals Inc	Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
TWI262914B (en) *	1999-07-02	2006-10-01	Agouron Pharma	Compounds and pharmaceutical compositions for inhibiting protein kinases
DE60028054T2 (de) *	1999-09-08	2006-12-21	Genentech, Inc., South San Francisco	Fibroblasten-wachstumsfaktor-19 (fgf-19) nukleinsäure und polypeptide und verfahren zu deren verwendung für behandlung von fettleibigkeit
US20020150575A1 (en) *	2000-01-07	2002-10-17	Cook Mark E.	Method to suppress appetite and reduce weight gain
US6573293B2 (en) *	2000-02-15	2003-06-03	Sugen, Inc.	Pyrrole substituted 2-indolinone protein kinase inhibitors
JP2003528632A (ja) *	2000-03-31	2003-09-30	インスティティ・パスツール	血管内皮成長因子（ｖｅｇｆ）−媒介性脈管形成を阻害するペプチド、該ペプチドをエンコードするポリヌクレオチド及びその使用方法
SE0001285D0 (sv) *	2000-04-07	2000-04-07	Elinus Ab	Djur- och cellmodeller för diabetes typ II och deras användning
MY128449A (en) *	2000-05-24	2007-02-28	Sugen Inc	Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
ATE295354T1 (de) *	2000-08-18	2005-05-15	Agouron Pharma	Heterozyklische-hydroximino-fluorene und ihre verwendung zur inhibierung von proteinkinasen
US6599902B2 (en) *	2001-05-30	2003-07-29	Sugen, Inc.	5-aralkysufonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
IL159177A0 (en) *	2001-06-20	2004-06-01	Prochon Biotech Ltd	Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
AR039067A1 (es) *	2001-11-09	2005-02-09	Pfizer Prod Inc	Anticuerpos para cd40
ES2363765T3 (es) *	2002-01-31	2011-08-16	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Agonistas de fgfr.
AU2003236557B2 (en) *	2002-06-27	2009-10-01	Verva Pharmaceuticals Pty Ltd	Differentiation modulating agents and uses therefor
CA2762955A1 (en)	2003-10-16	2005-04-28	Imclone Llc	Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof

2004
- 2004-10-18 CA CA2762955A patent/CA2762955A1/en not_active Abandoned
- 2004-10-18 ES ES04796034T patent/ES2361917T3/es not_active Expired - Lifetime
- 2004-10-18 SI SI200431700T patent/SI1680140T1/sl unknown
- 2004-10-18 US US10/575,977 patent/US20070274981A1/en not_active Abandoned
- 2004-10-18 JP JP2006535458A patent/JP4686465B2/ja not_active Expired - Fee Related
- 2004-10-18 AT AT04796034T patent/ATE506077T1/de active
- 2004-10-18 CA CA002542638A patent/CA2542638A1/en not_active Abandoned
- 2004-10-18 DK DK04796034.9T patent/DK1680140T3/da active
- 2004-10-18 EP EP10162585A patent/EP2229955A1/en not_active Withdrawn
- 2004-10-18 DE DE602004032370T patent/DE602004032370D1/de not_active Expired - Lifetime
- 2004-10-18 PL PL04796034T patent/PL1680140T3/pl unknown
- 2004-10-18 EP EP08020599A patent/EP2060270A3/en not_active Withdrawn
- 2004-10-18 WO PCT/US2004/034970 patent/WO2005037235A2/en not_active Ceased
- 2004-10-18 EP EP04796034A patent/EP1680140B1/en not_active Expired - Lifetime
- 2004-10-18 PT PT04796034T patent/PT1680140E/pt unknown
2011
- 2011-05-20 CY CY20111100497T patent/CY1111479T1/el unknown
- 2011-12-16 US US13/328,147 patent/US8263074B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2542638A1 (en)	2005-04-28
PT1680140E (pt)	2011-05-31
EP1680140A2 (en)	2006-07-19
SI1680140T1 (sl)	2011-08-31
JP4686465B2 (ja)	2011-05-25
US8263074B2 (en)	2012-09-11
US20120121609A1 (en)	2012-05-17
CY1111479T1 (el)	2015-08-05
EP2229955A1 (en)	2010-09-22
DK1680140T3 (da)	2011-06-14
WO2005037235A2 (en)	2005-04-28
EP1680140B1 (en)	2011-04-20
DE602004032370D1 (de)	2011-06-01
EP2060270A3 (en)	2009-12-09
CA2762955A1 (en)	2005-04-28
ATE506077T1 (de)	2011-05-15
WO2005037235A3 (en)	2005-12-22
EP2060270A2 (en)	2009-05-20
ES2361917T3 (es)	2011-06-24
EP1680140A4 (en)	2007-12-05
JP2008501302A (ja)	2008-01-24
US20070274981A1 (en)	2007-11-29

Publication	Publication Date	Title
PT1680140E (pt)	2011-05-31	Inibidores do receptor-1 do factor de crescimento de fibroblastos e m?todos de tratamento destes
EP2258722A3 (en)	2011-10-12	Antibodies to fibroblast growth factor-like (FGF-like) polypeptides
HUE048539T2 (hu)	2020-07-28	Eljárás szénhidrogének és oxigéntartalmú vegyületek elõállítására biomasszából, amely eljárás magában foglal fermentációt aminosavak (LEU, ILE, VAL) hozzáadásával
DE69940219D1 (de)	2009-02-12	Charakterisierung von Genfunktion an Hand doppelsträngiger-RNS Inhibition
DE60335195D1 (de)	2011-01-13	Mutante e. coli-appa-phytaseenzyme und natürliche varianten davon, solche phytaseenzyme codierende nukleinsäuren, diese enthaltende vektoren und wirtszellen und verfahren zur herstellung und verwendung davon
RU2005136013A (ru)	2007-05-27	Фосфодиэстераза 8а
DE60311470D1 (de)	2007-03-15	Verfahren zur reinigung von interleukin-4 und seinen muteinen
WO2002092758A8 (en)	2003-02-20	Gastrokines and derived peptides including inhibitors
ATE312939T1 (de)	2005-12-15	Verfahren zur rekombinanten herstellung von polypeptiden
WO2003048325A3 (en)	2003-10-09	Nucleotide sequences of shrimp beta-actin and actin promoters and their use in genetic transformation technology
MA	2019	High expression level of human epidermal growth factor (hEGF) using a well-designed fusion protein-tagged construct in E. coli.
SI1545428T1 (sl)	2010-03-31	Postopek zniževanja agregatnih nivojev pegiliranega proteina
NO20013617D0 (no)	2001-07-23	Fremgangsmåte ved kontrollert etterisoleringsproduksjon av proteiner i vertsorganismer
AU6839900A (en)	2001-03-19	Nucleic acid molecule comprising a nucleic acid sequence which codes for a haemocyanin, and comprising at least one intron sequence
WO2002101069A3 (en)	2003-09-04	Ns4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders
AU2003902414A0 (en)	2003-06-05	Flowering induction
WO2005047487A3 (en)	2006-04-13	Motoneuronotrophic factor gene sequences
AU2003280929A1 (en)	2004-06-30	A baldness related gene and the polypeptide encoded thereby, and uses thereof
ATE423200T1 (de)	2009-03-15	Neues plexin-polypeptid, dieses codierende dna und verwendung davon
WO2006073587A3 (en)	2009-05-07	Hemipteran 5-hydroxytryptamine 7 serotonin receptor
WO2001021794A3 (en)	2001-10-25	Smad associating polypeptides
RU95114524A (ru)	1997-07-20	Днк, белки, антитела, растение, способ получения масла, микробный хозяин, фрагмент днк
WO2004058161A3 (en)	2005-12-29	Hemipteran polo-like kinases